Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness and safety of ponatinib (Iclusig®) in patients with BCR-ABL positive acute lymphoblastic leukemia (ALL) in standard clinical practice in Europe.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • BCR-ABL Positive Acute Lymphoblastic Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT number NCT03515785
Study type Observational
Source Incyte Corporation
Contact
Status Withdrawn
Phase
Start date December 31, 2018
Completion date March 2021